Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
07:33am, Wednesday, 12'th Feb 2025
NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and develop
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
07:30am, Wednesday, 12'th Feb 2025
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor con
These Stocks Missed on Earnings, But Will Rebound Next Quarter
08:35am, Monday, 10'th Feb 2025
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
3 Fabulous Dividend Stocks to Buy in February
02:30pm, Sunday, 09'th Feb 2025
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks t
3 Dividend Stocks to Double Up on Right Now
05:43am, Sunday, 09'th Feb 2025
What's better than a good thing? More of a good thing.
These 2 Dividend Stocks Are Absolute Bargains Right Now
08:30am, Saturday, 08'th Feb 2025
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excell
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
08:00am, Saturday, 08'th Feb 2025
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I high
US FDA approves AbbVie's treatment for intra-abdominal infections
01:38pm, Friday, 07'th Feb 2025
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.
EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gr
The Zacks Analyst Blog Walmart, Visa, AbbVie and AstroNova
02:37am, Friday, 07'th Feb 2025
Walmart, Visa, AbbVie and AstroNova are included in this Analyst Blog.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:05am, Thursday, 06'th Feb 2025
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Top AI-Powered Biotech Stocks to Buy in February
09:45am, Thursday, 06'th Feb 2025
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-ch
Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
08:05am, Thursday, 06'th Feb 2025
Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle® and Share Their Personal Stories. Natrelle® is the #1 Selected Breast Implant by Leading U.S. Physicians* O
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
01:25pm, Wednesday, 05'th Feb 2025
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
11:31am, Monday, 03'rd Feb 2025
Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.
